Europe Launches Major Initiative to Eliminate Forever Chemicals from Medicine
Wageningen, Wednesday, 30 September 2026.
Wageningen University has joined the newly launched PFAROS consortium, a five-year European initiative dedicated to developing safe, chemical-free alternatives for the pharmaceutical and medical industries.
Addressing the Healthtech and Medical Sectors
This newly launched initiative represents a critical development at the intersection of the medicine and healthtech sectors [1][2]. Per- and polyfluoroalkyl substances (PFAS), colloquially known as “forever chemicals,” have historically been valued in medical manufacturing for their unique chemical properties, including durability, water resistance, and thermal stability [GPT]. However, their environmental persistence and potential bioaccumulation have triggered a major regulatory push across Europe [GPT]. The PFAROS consortium, which officially launched on September 29, 2026, aims to eliminate these persistent chemicals by designing viable, safe, and sustainable alternatives specifically tailored for medical devices, equipment components, and pharmaceutical products [2][4].
The Principles and Benefits of Safer Alternatives
The primary benefit of this innovation is the mitigation of environmental and toxicological risks without compromising the strict performance standards required in healthcare settings [1][2]. By transitioning away from PFAS, the medical industry can preemptively align with tightening European environmental regulations, ensuring that future medical devices do not contribute to long-term chemical pollution [GPT]. The project operates under the “Safe and Sustainable by Design” (SSbD) framework [1][2]. This methodology ensures that any new material proposed as a PFAS replacement is evaluated for its entire lifecycle impact, from initial synthesis to its ultimate end-of-life disposal, ensuring that the alternative does not introduce new, unforeseen environmental hazards [1][2].
How the Innovation Works
To achieve these ambitious goals, researchers are working at a laboratory scale to systematically identify and develop substitute materials for PFAS-containing parts in medical utilities [1][2]. Under the leadership of project leader Rian Ruhl, the scientific process is split into three main pillars: material development, toxicological evaluation, and advanced wastewater treatment [1][2]. Specifically, Wageningen Food & Biobased Research is leading the design of new bio-compatible materials and advanced water purification techniques, while Wageningen Food Safety Research is responsible for the rigorous toxicological screening of the newly developed alternatives [1][2]. This dual-action approach ensures that while new materials are being synthesized, medical wastewater treatment systems are simultaneously optimized to capture and filter out any remaining legacy PFAS residues before they enter municipal water systems [1][2].
Consortium Structure and European Support
The PFAROS initiative is a massive collaborative effort spanning five years and uniting a large-scale project consortium of 89 industrial and academic partners [2][4]. Wageningen University & Research (WUR), based in Wageningen, Netherlands, is a key academic contributor to the project [1][GPT]. This five-year endeavor is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 10125128 1 [1][2]. The IHI JU receives backing from the European Union’s Horizon Europe research and innovation program, alongside prominent industry trade associations including COCIR, EFPIA, Europa Bio, MedTech Europe, and Vaccines Europe [1][2]. This coordinated action reflects a broader trend of significant investments within the European healthtech ecosystem, mirroring other regional advancements such as the €2.5 million high-tech laboratory campus being developed by apis labor GmbH in Klagenfurt, Austria, to bolster localized pharmaceutical and microbiology research [3].